India/China/Brazil semaglutide generics risk: patent expiry enables steep ex-US ASP declines
Key Questions
When does the semaglutide patent expire outside the US?
The patent expires in March 2026, enabling generics in markets like India, China, and Brazil. This is expected to lead to significant price declines.
How much will semaglutide prices drop due to generics in India?
Prices are projected to fall 36-48% to ₹1290 via over 40 generics. Novo Nordisk is responding with local tie-ups and price cuts.
What risks do generics pose to Novo Nordisk in China and Brazil?
Jefferies estimates a $1B risk from generics in China and Brazil post-patent expiry. Competition is intensifying with local manufacturers.
Which companies are involved in semaglutide generics outside the US?
Companies like Poviztra, Emcure, and Korean firm Samchundang are key players. Samchundang is targeting orals and positioning against Novo in Korea.
How is Novo Nordisk responding to generic semaglutide competition?
Novo is pursuing local tie-ups and price cuts, such as in India. This strategy counters the crowding from generics post-March 2026 expiry.
Mar2026 expiry →36-48% cuts ₹1290 via 40+ generics; China/Brazil/Jefferies $1B risk; tie-ups Poviztra/Emcure etc.; Korean Samchundang orals; Sun Pharma Noveltreat ~$10/wk.